Biotech's big conference living up to reputation with big deals, big costs
Biotech's biggest dealmaking conference is off to a big start, and it may mark a return of the biotech IPO market as well as mergers and acquisitions.
Eli Lilly and Co. (NYSE: LLY) said Monday it would pay $8 billion for Loxo Oncology Inc., an East Coast cancer-fighting company with Bay Area ties. That follows Sunday night's announcement of deal between Foster City-based Gilead Sciences Inc. (NASDAQ: GILD) and a South Korean company to develop a treatment for nonalcoholic steatohepatitis — NASH…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Ron Leuty Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Conferences | Health Management | Mergers and Aquisitions | South Korea Health